Paper39375168
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.
Grisham R and 20 others. Int J Gynecol Cancer, 2025. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer. Papers, record 39375168. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39375168
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.
- PubMed
- Publication types
- Clinical Trial Protocol, Journal Article, Research Support, N.I.H., Extramural
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Cystadenocarcinoma, Serous | Major topic |
| Neoplasm Recurrence, Local | Major topic |
| Ovarian Neoplasms | Major topic |
| Female | |
| Humans | |
| Clinical Trials, Phase III as Topic | |
| Randomized Controlled Trials as Topic | |
| Multicenter Studies as Topic |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed |
Source NIH RePORTER
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06072781 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Derived from the trial | Yes |
Source ClinicalTrials.gov
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42891872 | Histotype and molecular subtype integration in epithelial ovarian cancer: implications for targeted treatment. | Cancer Metastasis Rev | 2026 | https://conductscience.org/library/papers/42891872 | PubMed |
| 42811335 | Targeting cancer-associated fibroblasts: therapeutic strategies, translational challenges, and future perspectives. | J Hematol Oncol | 2026 | https://conductscience.org/library/papers/42811335 | PubMed |
| 42798981 | Focal adhesion kinase inhibitor defactinib enhances olaparib-induced suppression of BRCA-proficient breast cancer cell proliferation. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42798981 | PubMed |
| 42699673 | Serous borderline tumor progressing to low-grade serous carcinoma after 35 years: a case of extended latency with molecular evidence of clonal relationship. | Gynecol Oncol Rep | 2026 | https://conductscience.org/library/papers/42699673 | PubMed |
| 42579369 | Combined FAK and MEK inhibition suppresses chromosome 8 gain malignant peripheral nerve sheath tumors. | J Clin Invest | 2026 | https://conductscience.org/library/papers/42579369 | PubMed |
| 41899597 | An FAK Kinase/Scaffold Mode-Switch in Dormancy and Resistance. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41899597 | PubMed |
| 41826571 | Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances. | Mol Biomed | 2026 | https://conductscience.org/library/papers/41826571 | PubMed |
| 41796449 | Disarming cancer resistance: FAK as a therapeutic target. | Trends Cancer | 2026 | https://conductscience.org/library/papers/41796449 | PubMed |
| 41751910 | Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41751910 | PubMed |
| 41675738 | Avutometinib (Avmapki): oral RAF/MEK clamp inhibitor advancing precision therapy in KRAS-mutant low-grade serous ovarian cancer. | Ann Med Surg (Lond) | 2026 | https://conductscience.org/library/papers/41675738 | PubMed |
| 41584508 | Recent FDA-approved kinase inhibitors for cancer therapy in 2025: A comprehensive review and perspectives. | EXCLI J | 2025 | https://conductscience.org/library/papers/41584508 | PubMed |
| 41392193 | Divergent oncogenic signaling and immune microenvironment changes in low-grade serous ovarian cancer patients undergoing intraperitoneal chemotherapy. | NPJ Precis Oncol | 2025 | https://conductscience.org/library/papers/41392193 | PubMed |
| 41193397 | Unmet needs and emerging therapeutics in low-grade serous ovarian carcinoma: from chemoresistance to precision medicine. | Future Oncol | 2025 | https://conductscience.org/library/papers/41193397 | PubMed |
| 41041285 | Medicinal chemistry perspectives on anticancer drug design based on clinical applications (2015-2025). | RSC Adv | 2025 | https://conductscience.org/library/papers/41041285 | PubMed |
| 40958869 | Evaluation of anti-liver cancer activity and anticancer mechanism of one novel small molecule compound (THY-10A62) targeting FAK pathway. | Front Oncol | 2025 | https://conductscience.org/library/papers/40958869 | PubMed |
| 40908761 | Cancer of the ovary, fallopian tube, and peritoneum: 2025 update. | Int J Gynaecol Obstet | 2025 | https://conductscience.org/library/papers/40908761 | PubMed |
| 40797342 | Therapeutic landscape of ovarian cancer: recent advances and emerging therapies. | Biomark Res | 2025 | https://conductscience.org/library/papers/40797342 | PubMed |
| 40762779 | Avutometinib and Defactinib: First Approval. | Drugs | 2025 | https://conductscience.org/library/papers/40762779 | PubMed |
| 40644648 | Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. | J Clin Oncol | 2025 | https://conductscience.org/library/papers/40644648 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| DTL | 51514 | PubTator's text mining | https://conductscience.org/library/genes/51514 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| MAP2K7 | 5609 | PubTator's text mining | https://conductscience.org/library/genes/5609 | NCBI Gene |
| PTK2 | 5747 | PubTator's text mining | https://conductscience.org/library/genes/5747 | NCBI Gene |
| ZHX2 | 22882 | PubTator's text mining | https://conductscience.org/library/genes/22882 | NCBI Gene |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| DEFACTINIB | CHEMBL3137331 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3137331 | ChEMBL |
| AVUTOMETINIB | CHEMBL3264002 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3264002 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39375168
GET https://conductscience.org/api/papers/v1/39375168/authors?page=2